AVIR
NASDAQAtea Pharmaceuticals Inc.
Website
News25/Ratings12
News · 26 weeks27-100%
2025-10-262026-04-19
Mix1590d
- Insider7(47%)
- Other3(20%)
- Earnings2(13%)
- SEC Filings2(13%)
- Offering1(7%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Atea Pharmaceuticals Inc.SCHEDULE 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
- PRReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COOAdditions Bring Extensive Capital Markets and Business Transaction Expertise to Company as it Advances Pegtarazimod into Late-Stage Clinical Trials ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointments of Howard Berman, Ph.D., as Chairman and Chief Executive Officer and Kia Motesharei, Ph.D., as President and Chief Operating Officer. Dr. Berman, who has served as Executive Chairman since November 2025, will lead ReAlta's overall strategy, clinical development, and corporate execution, while Dr.
- INSIDEROfficer Corcoran Andrea exercised 60,000 shares at a strike of $1.24, increasing direct ownership by 8% to 823,576 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SECSEC Form 10-K filed by Atea Pharmaceuticals Inc.10-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- SECAtea Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- PRAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateAdvanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026 Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care Expanded Antiviral Pipeline with New Hepatitis E Virus (HEV) Program; Lead Product Candidate AT-587 Expected
- PRAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 5, 2026, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2025, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Phar
- PRAtea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced in vitro results showing that two proprietary oral nucleotide analogs, AT-587 and AT-2490, exhibit promising antiviral profiles as potential first-in-class inhibitors for the treatment of Hepatitis E virus (HEV) infection, a positive-sense, single-stranded RNA virus that primarily infec
- SECSEC Form SCHEDULE 13G filed by Atea Pharmaceuticals Inc.SCHEDULE 13G - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
- INSIDERChief Medical Officer Horga Maria Arantxa converted options into 51,283 shares and covered exercise/tax liability with 16,073 shares, increasing direct ownership by 58% to 96,086 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDERChief Commercial Officer Vavricka John converted options into 42,083 shares and covered exercise/tax liability with 11,570 shares, increasing direct ownership by 59% to 82,594 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDERChief Development Officer Hammond Janet Mj converted options into 58,050 shares and covered exercise/tax liability with 14,136 shares, increasing direct ownership by 52% to 127,665 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDEROfficer Corcoran Andrea converted options into 54,866 shares and covered exercise/tax liability with 16,104 shares, increasing direct ownership by 5% to 763,576 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDERPresident, CEO, and Chairman Sommadossi Jean-Pierre covered exercise/tax liability with 106,093 shares and exercised 572,983 shares at a strike of $0.65, increasing direct ownership by 155% to 767,830 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDEREVP, Chief Accounting Officer Foster Wayne converted options into 41,333 shares and covered exercise/tax liability with 12,132 shares, increasing direct ownership by 58% to 79,329 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SECAtea Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- PRAtea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare ConferencePhase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End 2026 C-BEYOND and C-FORWARD Are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HCV Initiation of HEV Phase 1 Clinical Program for Product Candidate AT-587 Anticipated Mid-2026 BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious
- PRAtea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 7:30 a.m. PT in San Francisco, CA. A live webcast of the presentation will be available here and on the Company's website at https://ir.ateapharma.com. An archived webcast will be available on Atea's w
- PRAtea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C VirusEnrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America, Enrollment Completion Expected Mid-2026 with Topline Results Anticipated Year-End 2026 C-BEYOND AND C-FORWARD are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HCV BOSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced completion o
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Atea Pharmaceuticals Inc.SCHEDULE 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
- PRReAlta Life Sciences Appoints Dr. Howard Berman as Executive ChairmanReAlta Life Sciences Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Howard Berman, Ph.D., as Executive Chairman of the ReAlta Life Sciences Board of Directors, effective immediately. "We are delighted to welcome Howard to ReAlta at a pivotal moment for the Company as we move towards meaningful catalysts," said Kenji Cunnion, M.D., MPH, Co-Founder, Chief Medical Officer and Board Member of ReAlta. "His proven track record in advancing innovative immunology-based therapies and creatin
- PRAtea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare ConferenceBOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 10:00 a.m. ET in Coral Gables, FL. A live webcast of the presentation will be available here and on the Company's website at https://ir.ateapharma.com. An archived webcast will be a
- SECSEC Form 10-Q filed by Atea Pharmaceuticals Inc.10-Q - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- SECAtea Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- PRAtea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business UpdatePatient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026 New Data Show Bemnifosbuvir Has Unique Dual Mechanism Against HCV New Data Presented at The Liver Meeting®, the Annual Meeting of AASLD, Support Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Therapy for the Treatment of HCV Company Announces New Hepatitis E Virus (HEV) Development Program Company Holding Conference Call Today at 4:30 PM ET Company Hosting HCV KOL Event November 13th at 10 AM ET BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceut